Everything below concerns glucagon receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-08-12. Where a claim depends on a specific study, the study is described rather than over-claimed.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Nitrilotriacetic acid (NTA) is the aminopolycarboxylic acid with the formula N(CH2CO2H)3. It is a colourless solid. Its conjugate base nitrilotriacetate is used as a chelating agent for Ca2+, Co2+, Cu2+, and Fe3+.
Raleigh's industrial base includes financial services, electrical, medical, electronic and telecommunications equipment, clothing and apparel, food processing, paper products, and pharmaceuticals. Raleigh is part of North Carolina's Research Triangle, one of the country's largest and most successful research parks, and a major center in the United States for high-tech and biotech research, as well as advanced textile development. The city is a major retail shipping point for eastern North Carolina and a wholesale distributing point for the grocery industry. The healthcare and pharmaceutical industry has experienced major growth in recent years with many companies based in Raleigh including PRA Health Sciences, Chiesi USA (subsidiary of Chiesi Farmaceutici), formerly Mallinckrodt prior to tax inversion to Ireland, MAKO Surgical Corp., Metabolon, Inc., TearScience, and American Board of Anesthesiology. Companies based in Raleigh include Advance Auto Parts, Bandwidth, Building Materials Holding Corporation, Capitol Broadcasting Company, First Citizens BancShares, Golden Corral, Japan Tobacco International, Martin Marietta Materials, PRA Health Sciences, Red Hat, Vontier, Waste Industries, and Lulu. Social Blade, a website that tracks social media statistics and analytics, and Temple Run developer Imangi Studios are based in Raleigh. The North Carolina Air National Guard, a unit of the Air National Guard, is also headquartered in Raleigh. In April 2014 Steven P. Rosenthal of Northland Investment Corp. referred to Raleigh as "a real concentration of brain power.
=== Antimicrobial === Sweat may serve an antimicrobial function, like that of earwax or other secretory fluids (e.g., tears, saliva, and milk). It does this through a combination of glycoproteins that either bind directly to, or prevent the binding of microbes to, the skin and seem to form part of the innate immune system. In 2001, researchers at Eberhard-Karls University in Tübingen, Germany, isolated a large protein called dermcidin from skin. This protein, which could be cleaved into other antimicrobial peptides, was shown to be effective at killing some species of bacteria and fungi that affect humans, including Escherichia coli, Enterococcus faecalis, Staphylococcus aureus, and Candida albicans. It was active at high salt concentrations and in the acidity range of human sweat, where it was present at concentrations of 1–10 mg/ml.
Frydman RB, Tomaro ML, Frydman B (1972). "Pyrrolooxygenase: its action on tryptophan-containing enzymes and peptides". Biochim. Biophys. Acta. 284 (1): 80–9. doi:10.1016/0005-2744(72)90047-2. PMID 4403729.
== See also == Category:Cutaneous conditions Dermatology List of conditions associated with café au lait macules List of contact allergens List of cutaneous conditions associated with increased risk of nonmelanoma skin cancer List of cutaneous conditions associated with internal malignancy List of cutaneous conditions caused by mutations in keratins List of cutaneous neoplasms associated with systemic syndromes List of cutaneous conditions caused by problems with junctional proteins List of dental abnormalities associated with cutaneous conditions List of genes mutated in cutaneous conditions List of genes mutated in pigmented cutaneous lesions List of histologic stains that aid in diagnosis of cutaneous conditions List of human leukocyte antigen alleles associated with cutaneous conditions List of immunofluorescence findings for autoimmune bullous conditions List of inclusion bodies that aid in diagnosis of cutaneous conditions List of keratins expressed in the human integumentary system List of migrating cutaneous conditions List of mites associated with cutaneous reactions List of radiographic findings associated with cutaneous conditions List of specialized glands within the human integumentary system List of spiders associated with cutaneous reactions List of target antigens in pemphigoid List of target antigens in pemphigus List of verrucous carcinoma subtypes List of xanthoma variants associated with hyperlipoproteinemia subtypes
Sources: en.wikipedia.org
While there were well-known gyms throughout the country during the 1950s (such as Vince's Gym in North Hollywood, California, and Vic Tanny's chain gyms), there were still segments of the United States that had no "hardcore" bodybuilding gyms until the advent of Gold's Gym in the mid-1960s. Finally, the famed Muscle Beach in Santa Monica continued its popularity as the place to be for witnessing acrobatic acts, feats of strength, and the like. The movement grew more in the 1960s with increased TV and movie exposure, as bodybuilders were typecast in popular shows and movies.
Frequent lineup changes followed through the rest of the 1970s, and the band broke up in 1982 with Simmons the only constant member having appeared on all of their albums. In 1987, the Doobie Brothers reformed with Johnston back in the fold. McDonald, who made several guest appearances after their reformation, returned full-time in 2019. The group's sixteen studio albums include six top-ten appearances on the Billboard 200 album chart. Their 1978 album Minute by Minute reached number one for five weeks, and won a Grammy for Best Pop Vocal Performance by a Duo or Group. Their song "What a Fool Believes" from that album, written by McDonald and Kenny Loggins, won two Grammys, including Song of the Year and Record of the Year. The band had 16 Billboard Hot 100 top-40 hits, including "Listen to the Music", "Jesus Is Just Alright", "Long Train Runnin'", "China Grove", "Black Water" (#1 in 1974), "Takin' It to the Streets", "What a Fool Believes" (#1 in 1979), and "The Doctor", all of which receive rotation on classic hits radio stations. They have also released six live albums and numerous greatest hits compilations, including 1976's Best of the Doobies, certified diamond by the RIAA for reaching album sales of ten million copies. The Doobie Brothers were inducted into the Vocal Group Hall of Fame in 2004, and the Rock and Roll Hall of Fame in 2020. The group has sold more than 40 million records worldwide.
=== Toxicity of sulfur compounds === When sulfur burns in air, it produces sulfur dioxide. In water, this gas produces sulfurous acid and sulfites; sulfites are antioxidants that inhibit growth of aerobic bacteria and a useful food additive in small amounts. At high concentrations these acids harm the lungs, eyes, or other tissues. In organisms without lungs such as insects, sulfite in high concentration prevents respiration. Sulfur trioxide (made by catalysis from sulfur dioxide) and sulfuric acid are similarly highly acidic and corrosive in the presence of water. Concentrated sulfuric acid is a strong dehydrating agent that can strip available water molecules and water components from sugar and organic tissue. The burning of coal and/or petroleum by industry and power plants generates sulfur dioxide (SO2) that reacts with atmospheric water and oxygen to produce sulfurous acid (H2SO3). These acids are components of acid rain, lowering the pH of soil and freshwater bodies, sometimes resulting in substantial damage to the environment and chemical weathering of statues and structures. Fuel standards increasingly require that fuel producers extract sulfur from fossil fuels to prevent acid rain formation. This extracted and refined sulfur represents a large portion of sulfur production. In coal-fired power plants, flue gases are sometimes purified. More modern power plants that use synthesis gas extract the sulfur before they burn the gas.
In chemistry, a hydroxy or hydroxyl group is a functional group with the chemical formula −OH and composed of one oxygen atom covalently bonded to one hydrogen atom. In organic chemistry, alcohols and carboxylic acids contain one or more hydroxy groups. Both the negatively charged anion HO−, called hydroxide, and the neutral radical HO·, known as the hydroxyl radical, consist of an unbonded hydroxy group. According to IUPAC definitions, the term hydroxyl refers to the hydroxyl radical (·OH) only, while the functional group −OH is called a hydroxy group.
Sources: en.wikipedia.org
In addition, NMR was now being used to investigate and supplement crystal structures, as exemplified by the determination of an isolated tetraloop-receptor motif structure published in 1997. Investigations such as this enabled a more precise characterization of the base pairing and base stacking interactions which stabilized the global folds of large RNA molecules. The importance of understanding RNA tertiary structural motifs was prophetically well described by Michel and Costa in their publication identifying the tetraloop motif: "...it should not come as a surprise if self-folding RNA molecules were to make intensive use of only a relatively small set of tertiary motifs. Identifying these motifs would greatly aid modeling enterprises, which will remain essential as long as the crystallization of large RNAs remains a difficult task".
The Kingdom of Hungary collapsed, and the Ottomans occupied parts of Banat and Crișana in 1541. Transylvania and Maramureș, along with the rest of Banat and Crișana, developed into a new state under Ottoman suzerainty, the Principality of Transylvania. The Reformation, initiated in Germany by Martin Luther in 1517, encouraged the spread of Protestantism across the region; by 1568, the Edict of Torda formally granted local communities the right to choose their own preachers, sanctioning the existence of four "received" religions (Catholicism, Lutheranism, Calvinism, and Unitarianism. The Romanians' Orthodox faith remained only tolerated, although they made up more than one-third of the population, according to 17th-century estimates. In June 1609, Gabriel Báthory freed the Romanian Orthodox clergy from both taxation and service demands. The princes of Transylvania, Wallachia, and Moldavia joined the Holy League against the Ottoman Empire in 1594. The Wallachian prince, Michael the Brave, united the three principalities under his rule in May 1600. The neighbouring powers forced him to abdicate in September, but he became a symbol of the unification of the Romanian lands in the 19th century. Although the rulers of the three principalities continued to pay tribute to the Ottomans, the most talented princes—Gabriel Bethlen of Transylvania, Matei Basarab of Wallachia, and Vasile Lupu of Moldavia—strengthened their autonomy.
In the United States, almost all public universities were founded, and are operated by state governments and rely on subsidies from their respective states. They often have large enrollments, extensive facilities, and large budgets. However, support for public universities has declined in recent decades, forcing many public universities to seek private donations or raise tuition and fees. The percentage of state appropriations at public universities has fallen from 78% in 1974 to 43% in 2000. States generally charge higher tuition to out-of-state students because in-state students or their parents have previously subsidized the university by paying state taxes. The oldest public universities in the United States are the University of Georgia, founded in 1785, and the University of North Carolina at Chapel Hill, founded in 1789. The College of William & Mary, founded in 1693, and Rutgers University, founded in 1766, were two of the nine colonial colleges. Both were private universities until the 20th century, with William & Mary becoming public in 1908 and Rutgers in 1945. Every state has at least one public university and the largest states have more than thirty. This is partly a result of 1862 Morrill Land-Grant Acts, which gave eligible states 30,000 acres (12,141 ha) of federal land to sell to finance public universities that emphasized studies in agriculture and mechanical arts. The University of Wisconsin, Iowa State University, Rutgers, the State University of New Jersey, and the University of Missouri were early land-grant colleges.
Gustavo Bounous was a research medical doctor. He was born in Luserna, Italy on July 10, 1928. He was educated at the University of Turin and at the University of Genoa. Then, he worked as a research fellow in surgery at the Indiana Medical Center. In 1963 he moved to Canada. He became a professor of surgery, successively at the Université de Sherbrooke, 1973–1985, after that, at McGill University, 1985–1993. He died at the age of 83 on December 29, 2011.
==== Distribution ==== The volume of distribution of THC is large and is approximately 10 L/kg (range 4–14 L/kg), which is due to its high lipid solubility. The plasma protein binding of THC and its metabolites is approximately 95 to 99%, with THC bound mainly to lipoproteins and to a lesser extent albumin. THC is rapidly distributed into well-vascularized organs such as lung, heart, brain, and liver, and is subsequently equilibrated into less vascularized tissue. It is extensively distributed into and sequestered by fat tissue due to its high lipid solubility, from which it is slowly released. THC is able to cross the placenta and is excreted in human breast milk.
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.